Published in Int J Cancer on July 15, 1990
A novel high-through-put assay for screening of pro-apoptotic drugs. Invest New Drugs (2002) 1.49
Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance. Br J Cancer (1996) 1.03
Doxorubicin selected multidrug-resistant small cell lung cancer cell lines characterised by elevated cytoplasmic Ca2+ and resistance modulation by verapamil in absence of P-glycoprotein overexpression. Br J Cancer (1991) 0.86
In vitro testing of chemotherapeutic drug combinations in acute myelocytic leukaemia using the fluorometric microculture cytotoxicity assay (FMCA). Br J Cancer (1993) 0.81
Characterization of the cytotoxic activity of the indoloquinoline alkaloid cryptolepine in human tumour cell lines and primary cultures of tumour cells from patients. Invest New Drugs (2008) 0.79
Specific binding of proinsulin C-peptide to human cell membranes. Proc Natl Acad Sci U S A (1999) 1.91
Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer. Ann Oncol (2009) 1.77
A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol (2001) 1.61
Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: prognosis and treatment of recurrences in a cohort study. Eur J Surg Oncol (2012) 1.58
Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients. J Clin Oncol (2004) 1.51
A systematic overview of chemotherapy effects in gastric cancer. Acta Oncol (2001) 1.46
Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer (1992) 1.37
A systematic overview of chemotherapy effects in breast cancer. Acta Oncol (2001) 1.36
The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy. Ann Oncol (2011) 1.33
Analysis of oligonucleotide probe affinities using surface plasmon resonance: a means for mutational scanning. Anal Biochem (1997) 1.24
Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study. Br J Cancer (2004) 1.17
Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients. Eur J Cancer (2003) 1.16
Hope for a cure and altruism are the main motives behind participation in phase 3 clinical cancer trials. Eur J Cancer Care (Engl) (2014) 1.11
Dynamics of nonstructural carbohydrates and biomass yield in a fodder legume tree at different harvest intensities. Tree Physiol (2001) 1.07
Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles. Br J Cancer (2005) 1.05
Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance. Br J Cancer (1996) 1.03
A systematic overview of chemotherapy effects in non-small cell lung cancer. Acta Oncol (2001) 1.02
Pharmacokinetic models for the saturable distribution of paclitaxel. Drug Metab Dispos (1999) 1.02
Affinity maturation of a Taq DNA polymerase specific affibody by helix shuffling. Protein Eng (1999) 0.99
Assessment of quality of life during chemotherapy. Acta Oncol (2001) 0.99
A systematic overview of chemotherapy effects in acute myeloid leukaemia. Acta Oncol (2001) 0.99
Management of menopause-related symptoms. Evid Rep Technol Assess (Summ) (2005) 0.98
Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients. Cancer Chemother Pharmacol (2006) 0.94
Cellular cytotoxic drug sensitivity in children with acute leukemia and Down's syndrome: an explanation to differences in clinical outcome? Leukemia (2000) 0.93
SDZ PSC-833--a novel potent in vitro chemosensitizer in multiple myeloma. Anticancer Drugs (1992) 0.93
Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors. Semin Oncol (1995) 0.92
Intraoperative hyperthermic versus postoperative normothermic intraperitoneal chemotherapy for colonic peritoneal carcinomatosis: a case-control study. Ann Oncol (2011) 0.90
Cytotoxic drug sensitivity testing of tumor cells from patients with ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA). Gynecol Oncol (1994) 0.90
Cytotoxic activity of calcein acetoxymethyl ester (Calcein/AM) on primary cultures of human haematological and solid tumours. Eur J Cancer (1996) 0.89
Relationship between diagnosis-specific activity of cytotoxic drugs in fresh human tumour cells ex vivo and in the clinic. Eur J Cancer (1999) 0.89
Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients. Eur J Clin Pharmacol (1998) 0.89
Guanidino-containing drugs in cancer chemotherapy: biochemical and clinical pharmacology. Biochem Pharmacol (2001) 0.89
Development of vincristine resistance and increased sensitivity to cyclosporin A and verapamil in the human U-937 lymphoma cell line without overexpression of the 170-kDa P-glycoprotein. Int J Cancer (1994) 0.89
A rapid fluorometric method for semiautomated determination of cytotoxicity and cellular proliferation of human tumor cell lines in microculture. Anticancer Res (1989) 0.89
Effects of lovastatin on a human myeloma cell line: increased sensitivity of a multidrug-resistant subline that expresses the 170 kDa P-glycoprotein. Anticancer Drugs (1994) 0.87
Vaginal birth after cesarean (VBAC). Evid Rep Technol Assess (Summ) (2003) 0.87
Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients. J Clin Oncol (1996) 0.87
Stability towards alkaline conditions can be engineered into a protein ligand. J Biotechnol (2000) 0.86
Alkaline single-cell gel electrophoresis and human biomonitoring for genotoxicity: a pilot study on breast cancer patients undergoing chemotherapy including cyclophosphamide. Mutat Res (1997) 0.86
Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients. Br J Cancer (1997) 0.85
EGFR, HER2 and HER3 expression in primary colorectal carcinomas and corresponding metastases: Implications for targeted radionuclide therapy. Oncol Rep (2011) 0.85
Postoperative adverse events and long-term survival after cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol (2008) 0.85
A systematic overview of chemotherapy effects in aggressive non-Hodgkin's lymphoma. Acta Oncol (2001) 0.85
In vitro determination of cytotoxic drug response in ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer (1997) 0.84
Calcium-activated calcium permeability in parathyroid cells. FEBS Lett (1986) 0.84
Quantitative investigation of the modular primer effect for DNA and peptide nucleic acid hexamers. Anal Biochem (1999) 0.84
Cellular drug sensitivity in MLL-rearranged childhood acute leukaemia is correlated to partner genes and cell lineage. Br J Haematol (2005) 0.84
Apoptosis induced by calcein acetoxymethyl ester in the human histiocytic lymphoma cell line U-937 GTB. Biochem Pharmacol (2000) 0.84
Outcome differences between debulking surgery and cytoreductive surgery in patients with Pseudomyxoma peritonei. Eur J Surg Oncol (2012) 0.83
Differential activity of topotecan, irinotecan and SN-38 in fresh human tumour cells but not in cell lines. Eur J Cancer (2000) 0.83
Pharmacokinetics of cisplatin during hyperthermic intraperitoneal treatment of peritoneal carcinomatosis. Eur J Clin Pharmacol (2012) 0.83
In vitro activity of 2-chlorodeoxyadenosine (CdA) in primary cultures of human haematological and solid tumours. Eur J Cancer (1994) 0.83
Cell death with atypical features induced by the novel antitumoral drug CHS 828, in human U-937 GTB cells. Eur J Pharmacol (2001) 0.82
A prospective study of the use of chemotherapy in Sweden and assessment of the use in relation to scientific evidence. Acta Oncol (2001) 0.82
Chemotherapeutic drug sensitivity testing of human leukemia cells in vitro using a semiautomated fluorometric assay. Leukemia (1990) 0.82
In vitro testing of chemotherapeutic drug combinations in acute myelocytic leukaemia using the fluorometric microculture cytotoxicity assay (FMCA). Br J Cancer (1993) 0.81
Cytotoxic effect of calcein acetoxymethyl ester on human tumor cell lines: drug delivery by intracellular trapping. Anticancer Drugs (1995) 0.81
In vitro analysis of drug resistance in tumor cells from patients with acute myelocytic leukemia. Med Oncol Tumor Pharmacother (1992) 0.81
Differential activity of Cremophor EL and paclitaxel in patients' tumor cells and human carcinoma cell lines in vitro. Cancer (1997) 0.81
The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of chemotherapy effects in some major tumour types--summary and conclusions. Acta Oncol (2001) 0.81
Characterization of four doxorubicin adapted human breast cancer cell lines with respect to chemotherapeutic drug sensitivity, drug resistance associated membrane proteins and glutathione transferases. Anticancer Res (1993) 0.80
Translocation t(1;19) is related to low cellular drug resistance in childhood acute lymphoblastic leukaemia. Leukemia (2005) 0.80
Combination of cyclosporin A and buthionine sulfoximine (BSO) as a pharmacological strategy for circumvention of multidrug resistance in small cell lung cancer cell lines selected for resistance to doxorubicin. Anticancer Res (1991) 0.80
A systematic overview of chemotherapy effects in ovarian cancer. Acta Oncol (2001) 0.80
In vivo activity of CHS 828 on hollow-fibre cultures of primary human tumour cells from patients. Cancer Lett (2001) 0.80
Microfluorometric evaluation of calcein acetoxymethyl ester as a probe for P-glycoprotein-mediated resistance: effects of cyclosporin A and its nonimmunosuppressive analogue SDZ PSC 833. Exp Cell Res (1994) 0.80
Bimodal regulation of secretion by cytoplasmic Ca2+ as demonstrated by the parathyroid. FEBS Lett (1987) 0.80
Cytotoxic activity of topoisomerase II inhibitors in primary cultures of tumor cells from patients with human hematologic and solid tumors. Cancer (1994) 0.80
A systematic overview of chemotherapy effects in pancreatic cancer. Acta Oncol (2001) 0.79
Characteristics of etoposide-induced apoptotic cell death in the U-937 human lymphoma cell line. Anticancer Drugs (2001) 0.79
A non-P-glycoprotein-mediated mechanism of vincristine transport which is affected by resistance modifiers and present in chemosensitive cells. Leukemia (1994) 0.79
A systematic overview of chemotherapy effects in indolent non-Hodgkin's lymphoma. Acta Oncol (2001) 0.79
A systematic overview of chemotherapy effects in urothelial bladder cancer. Acta Oncol (2001) 0.78
Antitumour activity of suramin analogues in human tumour cell lines and primary cultures of tumour cells from patients. Eur J Cancer (2000) 0.78
Heterogeneous activity of cytotoxic drugs in patient samples of peritoneal carcinomatosis. Eur J Surg Oncol (2007) 0.78
Cytoplasmic Ca2+ concentration of single normal human and bovine parathyroid cells measured by dual wavelength microfluorometry. Biosci Rep (1987) 0.78
Expression of the 85-kd membrane protein in primary human breast cancer: relationship to hormone receptor levels, DNA ploidy, and tumor grade. Hum Pathol (1995) 0.78
Hyperparathyroidism is associated with reduced expression of a parathyroid calcium receptor mechanism defined by monoclonal antiparathyroid antibodies. Endocrinology (1988) 0.78
Microphysiometry: new technology for evaluation of anticancer drug activity in human tumor cells in vitro. Anticancer Drugs (1998) 0.78
A hollow fiber model for in vitro studies of cytotoxic compounds: activity of the cyanoguanidine CHS 828. Anticancer Drugs (2001) 0.78
In vitro evaluation of new anticancer drugs, exemplified by vinorelbine, using the fluorometric microculture cytotoxicity assay on human tumor cell lines and patient biopsy cells. J Exp Ther Oncol (1996) 0.78
Early ionic events associated with phorbol ester induced differentiation and inhibition of cell growth in hematopoietic tumor cell lines. Anticancer Res (1989) 0.78
A systematic overview of chemotherapy effects in Hodgkin's disease. Acta Oncol (2001) 0.77
Activity of cyclosporins as resistance modifiers in primary cultures of human haematological and solid tumours. Br J Cancer (1994) 0.77
Verapamil and cyclosporin A potentiate the effects of chemotherapeutic drugs in the human medullary thyroid carcinoma TT cell line not expressing the 170 kDa P-glycoprotein. Cancer Lett (1990) 0.77
Selective sensitivity of solid tumors to suramin in primary cultures of tumor cells from patients. Int J Cancer (1995) 0.77
Prediction of individual patient response to chemotherapy by the fluorometric microculture cytotoxicity assay (FMCA) using drug specific cut-off limits and a Bayesian model. Anticancer Res (1994) 0.77
Effects of interferons and tumour necrosis factor-alpha on human lung cancer cell lines and the development of an interferon-resistant lung cancer cell line. Acta Oncol (1996) 0.77
In vitro activity of the novel cytotoxic agent CHS 828 in childhood acute leukemia. Anticancer Drugs (2002) 0.77
Interactions between cladribine (2-chlorodeoxyadenosine) and standard antileukemic drugs in primary cultures of human tumor cells from patients with acute myelocytic leukemia. Leukemia (1994) 0.77
Relationship between cytotoxic drug response patterns and activity of drug efflux transporters mediating multidrug resistance. Eur J Pharmacol (1998) 0.76
Difluoromethylornithine and ethylglyoxal bis(guanylhydrazone) as inhibitors of human renal carcinoma cell proliferation and polyamine metabolism. Anticancer Res (1993) 0.76
Monoclonal antiparathyroid antibodies revealing defect expression of a calcium receptor mechanism in hyperparathyroidism. World J Surg (1988) 0.76
P-glycoprotein expression and activity of resistance modifying agents in primary cultures of human renal and adrenocortical carcinoma cells. Anticancer Res (1994) 0.76
Evaluation of drug interactions in the established FEC regimen in primary cultures of tumour cells from patients. Ann Oncol (2000) 0.76
On the mechanism underlying calcein-induced cytotoxicity. Eur J Pharmacol (1999) 0.76
An explorative study on the clinical utility of baseline and serial serum tumour marker measurements in advanced upper gastrointestinal cancer. Oncol Rep (2010) 0.75
[Evidence-based use of the PET in cancer diagnosis?]. Lakartidningen (2000) 0.75